Trial Profile
A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Assessing the Dose-response Relationship of FE 999049 in Controlled Ovarian Stimulation in Japanese Women Undergoing an Assisted Reproductive Technology Programme
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Follitropin delta (Primary) ; Follitropin beta; Gonadotropin releasing hormone; Progesterone
- Indications Endometriosis; Female infertility
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 30 Nov 2020 Primary endpoint (Number of oocytes retrieved) has been met, according to results published in the Fertility and Sterility
- 30 Nov 2020 Results published in the Fertility and Sterility
- 21 Oct 2020 Results of post-hoc analysis from two clinical studies: NCT02309671 and NCT01426386 assessing ovarian response to different doses of follitropin delta between Japanese and non-Japanese population presented at the American Society for Reproductive Medicine Scientific Congress 2020